Biotech Co. Has Promising AI-Accelerated Pipeline
Research Report

1. Rakovina Therapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina Therapeutics Inc.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for First Berlin, Rakovina Therapeutics Inc., April 2, 2025

First Berlin Equity Research First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen. First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR). Anschrift: First Berlin Equity Research GmbH Friedrichstr. 69 10117 Berlin Germany Vertreten durch den Geschäftsführer: Martin Bailey Telefon: +49 (0) 30-80 93 9 680 Fax: +49 (0) 30-80 93 9 687 E-Mail: info@firstberlin.com Amtsgericht Berlin Charlottenburg HR B 103329 B UST-Id.: 251601797 Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV First Berlin Equity Research GmbH Authored by: Alexander Rihane, Analyst All publications of the last 12 months were authored by Alexander Rihane. Christian Orquera Company responsible for preparation: First Berlin Equity Research GmbH, Friedrichstraße 69, 10117 Berlin The production of this recommendation was completed on 2 April 2025 at 15:05 Person responsible for forwarding or distributing this financial analysis: Martin Bailey Copyright© 2025 First Berlin Equity Research GmbH No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request. INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II. First Berlin Equity Research GmbH (hereinafter referred to as: “First Berlin”) prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses. CONFLICTS OF INTEREST In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involving a conflict of interests carry on those activities at a level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients. In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates. With regard to the financial analyses of Rakovina Therapeutics Inc. the following relationships and circumstances exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the Rakovina Therapeutics Inc. for preparation of a financial analysis for which remuneration is owed. Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest:  The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0.5 % of the total issued share capital of the analysed company;  The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;  The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;  The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;  The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company; With regard to the financial analyses of Rakovina Therapeutics Inc. the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the Rakovina Therapeutics Inc. for preparation of a financial analysis for which remuneration is owed. In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees. INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014). First Berlin notes that is has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits. PRICE TARGET DATES Unless otherwise indicated, current prices refer to the closing prices of the previous trading day. AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY The present financial analysis is based on the author’s own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision. ASSET VALUATION SYSTEM First Berlin’s system for asset valuation is divided into an asset recommendation and a risk assessment. ASSET RECOMMENDATION The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows: Category 1 2 Current market capitalisation (in €) 0 - 2 billion > 2 billion Strong Buy¹ An expected favourable price trend of: > 50% > 30% Buy An expected favourable price trend of: > 25% > 15% Add An expected favourable price trend of: 0% to 25% 0% to 15% Reduce An expected negative price trend of: 0% to -15% 0% to -10% Sell An expected negative price trend of: < -15% < -10% ¹ The expected price trend is in combination with sizable confidence in the quality and forecast security of management. Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of €0 – €2 billion, and Category 2 companies have a market capitalisation of > €2 billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies. RISK ASSESSMENT The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models. RECOMMENDATION & PRICE TARGET HISTORY Report No.: Date of publication Previous day closing price Recommendation Price target Initial Report Today CAD0.10 Buy CAD0.40 INVESTMENT HORIZON Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months. UPDATES At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications. SUBJECT TO CHANGE The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification. Legally required information regarding  key sources of information in the preparation of this research report  valuation methods and principles  sensitivity of valuation parameters can be accessed through the following internet link: https://firstberlin.com/disclaimer-english-link/ 

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108,
53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main EXCLUSION OF LIABILITY (DISCLAIMER) RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information. RELIABILITY OF ESTIMATES AND FORECASTS The author of the financial analysis made estimates and forecasts to the best of the author’s knowledge. These estimates and forecasts reflect the author’s personal opinion and judgement. The premises for estimates and forecasts as well as the author’s perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments. Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future. Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts. INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances. The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis. A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document. NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information. NO OBLIGATION TO UPDATE First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company. DUPLICATION Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin. SEVERABILITY Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions. APPLICABLE LAW, PLACE OF JURISDICTION The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany). NOTICE OF DISCLAIMER By taking note of this financial analysis the recipient confirms the binding nature of the above explanations. By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient. QUALIFIED INSTITUTIONAL INVESTORS First Berlin financial analyses are intended exclusively for qualified institutional investors. This report is not intended for distribution in the USA and/or Canada.

On April 2, 2025, First Berlin Equity Research analysts Alexander Rihane and Christian Orquera initiated coverage of Rakovina Therapeutics Inc. (RKV:TSX.V) with a Buy rating and a price target of CA$0.40, highlighting the company's promising AI-accelerated pipeline of DNA Damage Response (DDR) compounds that position it for potential pharmaceutical partnership deals in the near term.

Rakovina is a pre-clinical stage biopharmaceutical company focused exclusively on developing next-generation anti-cancer compounds discovered through artificial intelligence (AI). The company's Deep Docking AI platform has been validated through real-world applications, including during the COVID-19 pandemic when it generated 1,000 potential drug candidates against SARS-CoV-2 in less than four weeks. Notably, a derivative of one of these compounds became the active ingredient in Pfizer's COVID drug Paxlovid. The platform's effectiveness has been further demonstrated by winning the international CACHE drug discovery competition twice in the last three years.

The company's lead program targets Poly ADP-Ribose Polymerase (PARP), a well-validated mechanism in oncology with first-generation PARP inhibitors marketed since 2014. Rakovina's kt-2000 next-generation PARP inhibitors are designed to address key limitations of current drugs, particularly poor brain penetration and high toxicity. The company aims to secure a licensing deal for this program in the second half of 2025 (First Berlin estimates: first half of 2026). Rakovina is also advancing an ATR inhibitor program (kt-5000), which is being prepared for out-licensing afterward (First Berlin estimates: second half of 2026).

The global PARP inhibitor market is projected to grow from US$4 billion in 2024 to US$16 billion by 2034, representing a compound annual growth rate of approximately 15%. The DDR space has seen strong deal activity, with around US$4.4 billion in total potential value across four major partnerships focused on ATR and PARP-1 inhibitors, demonstrating significant pharmaceutical industry interest in next-generation DDR therapeutics.

Upcoming catalysts include the presentation of two abstracts at the 2025 American Association for Cancer Research (AACR) Annual Meeting on April 25-30. These abstracts will present findings from in silico screening followed by in vitro and in vivo validation of the compounds' efficacy, selectivity, and pharmacokinetic properties — marking the first time Rakovina will publish real-world confirmation of their AI-generated compound data.

Key risks identified in the report include the company's small size and early-stage pipeline compared to peer DDR players, dependence on key staff, and the likelihood that Rakovina's compounds will not be first to market as competitor compounds are already in clinical testing. Financial risks are also significant, as failure to out-license the kt-2000 PARP inhibitor program would impact the company's ability to finance further development without substantial dilution.

The analysts value Rakovina at US$59.1 million based on a sum-of-the-parts methodology that applies a risk-adjusted net present value (rNPV) model for the lead drug candidates. With the share price at the time of the report at CA$0.10, the CA$0.40 target price represents a potential return of 300%.